The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AmMax Bio; Daiichi Sankyo/Lilly; Johnson & Johnson/Janssen; Onkos Surgical; Stryker
Travel, Accommodations, Expenses - Onkos Surgical; Stryker
A phase 2, open-label, adaptive, dose-ranging study with long-term extension to evaluate the safety, tolerability, efficacy, and pharmacokinetics of intra-articular AMB-05X injections in patients with tenosynovial giant cell tumor.
 
Hans Gelderblom
Research Funding - AmMax Bio (Inst); AmMax Bio (Inst); Daiichi (Inst); Deciphera (Inst); Ipsen (Inst); Novartis (Inst)
 
Vivek Bhadri
No Relationships to Disclose
 
R. Lor Randall
Honoraria - Biomet; Daiichi Sankyo; Onclive; Onkos Surgical; SpringWorks Therapeutics
Travel, Accommodations, Expenses - Biomet; Daiichi Sankyo/Lilly; SpringWorks Therapeutics
 
Thomas Scharschmidt
No Relationships to Disclose
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Adcendo; Amgen; AmMax Bio; Ayala Pharmaceuticals; Bayer; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; inhibrx; Kowa Pharmaceutical; Lilly; Medpacto; Servier
Research Funding - AmMax Bio (Inst); Avacta Life Sciences (Inst); BioAtla (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Theseus Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
Laman Alani
Employment - AmMax Bio
Stock and Other Ownership Interests - AmMax Bio
Research Funding - AmMax Bio
Patents, Royalties, Other Intellectual Property - AmMax Bio
 
Kirk Johnson
Employment - AmMax Bio
Leadership - AmMax Bio
Stock and Other Ownership Interests - AmMax Bio; Novartis Biociencias; Pfizer; Xoma
Consulting or Advisory Role - Xoma
Patents, Royalties, Other Intellectual Property - AmMax Bio
 
Stephanie Leyva
Employment - AmMax Bio
Stock and Other Ownership Interests - AmMax Bio
 
Dorothy D. Nguyen
Employment - AmMax Bio
Stock and Other Ownership Interests - AmMax Bio
Research Funding - AmMax Bio
Patents, Royalties, Other Intellectual Property - AmMax Bio
Travel, Accommodations, Expenses - AmMax Bio
Other Relationship - AmMax Bio
 
Tiffany Nguyen
Employment - AmMax Bio
Stock and Other Ownership Interests - AmMax Bio
 
Michiel A.J. van de Sande
Employment - Leiden University Medical Centre; Princess Máxima Center
Consulting or Advisory Role - AmMax Bio; CarboFix Orthopedics; Daiichi Sankyo Pharmaceutical; Deciphera; Implantcast
Research Funding - CarboFix Orthopedics; Daiichi Sankyo Pharmaceutical; Implantcast